|
|
|
|
|
| Available: 0 |
| List Price:$42.95 |
|
Other formats:
|
| Edition: | 1st |
| Publisher: | National Academies Press |
| ISBN: | 0-309-09214-0 (0309092140) |
| ISBN-13: | 978-0-309-09214-2 (9780309092142) |
| Format: | Proceedings MARCH 2021 |
| Binding: | Softcover |
| Copyright: | 2021 |
| Publish Date: | 01/22 |
| Weight: | 0.43 Lbs. |
| Pages: | 112 |
| Subject Class: | PUB (Public Health) |
| Return Policy: | Returns accepted up to 90 days provided no other recalls or return restrictions apply. |
| ProQuest Ebook Central: |
Available in ProQuest Ebook Central™ View
|
|
|
| |
| Discipline: | Pharmacology | | Subject Definition: | Drug Discovery; Chronic Disease | | NLM Class: | QV 744 | | LC Class: | RM301.25 | | Abstract: | Investment and innovation in drug research and development (R&D) for highly prevalent chronic diseases has stalled in recent decades, despite half of all Americans living with at least one chronic disease. As a result, prevalent chronic diseases are producing immense health care costs as well as preventable suffering and death. On February 22, March 2, and March 8, 2021, the National Academies of Sciences, Engineering, and Medicine, convened a workshop to discuss barriers to innovation in this space and examine strategies and incentives to support equitable, person-centered drug R&D for prevalent chronic diseases. |
|
|
|
|
|
|
|
|
Follow Matthews Book Co. on:
Copyright © 2001-2024 Matthews Book Company - All rights reserved. - 11559 Rock Island Ct., Maryland Heights, MO, 63043 - (800) MED-BOOK
Matthews